Who is the manufacturer of DRI ECSTASY ENZYME IMMUNOASSAY?

Microgenics Corp. filed the 510(k) submission for DRI ECSTASY ENZYME IMMUNOASSAY (K012110).

What is the FDA product code for DRI ECSTASY ENZYME IMMUNOASSAY?

DKZ. It is classified under 21 CFR 862.3100 as a Class 2 device in the Clinical Toxicology panel.

What is the regulatory pathway for DRI ECSTASY ENZYME IMMUNOASSAY?

510(k) clearance (submission type: Traditional).

What are the predicate devices for DRI ECSTASY ENZYME IMMUNOASSAY?

CEDIA DAU Amphetamines/Ecstasy Assay (K010496).

Who can help prepare an FDA 510(k) submission like DRI ECSTASY ENZYME IMMUNOASSAY?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

DRI ECSTASY ENZYME IMMUNOASSAY

K012110 · Microgenics Corp. · DKZ · Aug 27, 2001 · Clinical Toxicology

Device Facts

Record ID	K012110
Device Name	DRI ECSTASY ENZYME IMMUNOASSAY
Applicant	Microgenics Corp.
Product Code	DKZ · Clinical Toxicology
Decision Date	Aug 27, 2001
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 862.3100
Device Class	Class 2

Intended Use

The DRI Ecstasy Enzyme Immunoassay is a homogeneous enzyme immunoassay intended for the qualitative or semiquantitative determination of ecstasy drugs in human urine. The assay provides a simple and rapid analytical screening procedure for detecting ecstasy drugs at a Cutoff level of 500 ng/mL. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Device Story

Liquid, ready-to-use homogeneous enzyme immunoassay; detects ecstasy drugs in human urine. Principle: competition between G6PDH-labeled drug and free drug in sample for fixed antibody binding sites. In absence of free drug, antibody binds labeled drug, decreasing enzyme activity; direct relationship between drug concentration and enzyme activity. G6PDH activity measured spectrophotometrically at 340 nm via conversion of NAD to NADH. Used in clinical laboratories on automated chemistry analyzers. Provides preliminary screening results; requires GC/MS confirmation. Assists clinicians in identifying drug use or overdose; supports clinical decision-making.

Clinical Evidence

Bench testing only. Accuracy evaluated against GC/MS reference method with 100% agreement (92 true positives, 18 true negatives). Sensitivity (LOD) reported at 22 ng/mL. Precision studies showed total and within-run dose CVs <2.5%. Linearity established between 375 and 625 ng/mL. Specificity testing confirmed no interference from endogenous substances, pH variations, or structurally unrelated compounds.

Technological Characteristics

Homogeneous enzyme immunoassay. Reagents: Antibody/Substrate and Enzyme Conjugate. Sensing principle: Spectrophotometric measurement of G6PDH enzyme activity at 340 nm. Form factor: Liquid, ready-to-use. Connectivity: Designed for automated clinical chemistry analyzers. Sterilization: Not specified.

Indications for Use

Indicated for the qualitative or semiquantitative screening of ecstasy drugs in human urine at a 500 ng/mL cutoff. Intended for use as a preliminary analytical test; requires confirmation by GC/MS. For professional use in clinical settings.

Regulatory Classification

Identification

An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

CEDIA DAU Amphetamines/Ecstasy Assay (K010496)

Related Devices

K033094 — ECSTASY ENZYME IMMUNOASSAY, CATALOG # 0160 (500 TEST KIT), CATALOG # 0161 (5000 TEST KIT) · Lin-Zhi International, Inc. · Dec 19, 2003
K240670 — DRI Ecstasy Plus Assay · Microgenics Corporation · Oct 30, 2024
K033866 — CAMP MULTIPLE ANALYTE ENZYME IMMUNOASSAY, CAT.# 0510, 0511 (500 & 5000 TEST KITS) · Lin-Zhi International, Inc. · Apr 7, 2004
K113661 — LZI METHAMPHETAMINE ENZYME MMUNOASSAY, LZI METHAMPHETAMINE CALIBRATORS, LZI METHAMPHETAMINE CONTROLS · Lin-Zhi International, Inc. · Jan 23, 2012
K043028 — EMIT II PLUS ECSTASY ASSAY · Dade Behring, Inc. · Jan 7, 2005

Submission Summary (Full Text)

{0}------------------------------------------------ AUG 2 7 2001 Image /page/0/Picture/1 description: The image shows the logo for Microgenics. The logo consists of a circular design on the left, resembling a sun or a stylized flower, with numerous small, dark, wedge-shaped elements arranged in concentric circles. To the right of this design is the word "microgenics" in a bold, sans-serif font, with a horizontal line underlining the text. #### 510(k) Summary This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: K012 UU # Submitter Information (21 CFR 807.92(a)(1)) | Submitter: | Microgenics Corporation 46360 Fremont Boulevard Fremont, CA 94538 phone: (510) 979-5150 fax: (510)-979-5455 | |------------|-------------------------------------------------------------------------------------------------------------------------| | Contact: | Sherrie Rinne | Regulatory Specialist July 3, 2001 Summary date: # Name of Device and Classification (21 CFR 807.92(a)(2)) DRI® Ecstasy Enzyme Immunoassay Name (trade): Ecstasy Enzyme Immunoassay Name (usual): Amphetamines test system, 21 CFR 862.3100, Class II, DKZ (91) Classification: # Identification of Legally Marketed Predicate Device(s) (21 CFR 807,92 (a)(3)) DRI Ecstasy Enzyme Immunoassay is substantially equivalent to CEDIA DAU Amphetamines/Ecstasy Assay (Microgenics Corporation, Fremont, CA), cleared under premarket notification K010496 DRI Ecstasy Enzyme Immunoassay is identical or similar to its predicate in terms of intended use, method principle, device components, risk to the patient, and clinical performance. ### Description of Device (21 CFR 807.92 (a)(4)) The DRI Ecstasy Assay is a liquid ready-to-use homogeneous enzyme immunoassay. The assay uses specific antibodies, which can detect ecstasy drugs in urine with minimal cross-reactivity to various amphetamine compounds. The assay is based on competition between a drug labeled with glucose-6-phosphate dehydrogenase (G6PDH) enzyme, and free drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the specific antibody binds the drug labeled with G6PDH causing a decrease in enzyme activity. This phenomenon creates a direct relationship between drug concentration in urine and enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH. #### Microgenics Corporation {1}------------------------------------------------ ### Intended Use (21 CFR 807.92 (a)(5)) The DRI Ecstasy Enzyme Immunoassay is a homogeneous enzyme immunoassay intended for the qualitative or semiquantitative determination of ecstasy drugs in human urine. The assay provides a simple and rapid analytical screening procedure for detecting ecstasy drugs at a Cutoff level of 500 ng/mL. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. # Similarities to the Predicate(s) (21 CFR 807.92 (a)(6)) A summary table of the similarities and difference between DRI Ecstasy Enzyme Immunoassay and the predicate device follows. #### Comparison Table: | Device Name | CEDIA DAU Amphetamines/Ecstasy Assay (K010496) | DRI Ecstasy Enzyme Immunoassay (new device) | |-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Indications for Use | The CEDIA DAU Amphetamines / Ecstasy Assay is a homogeneous enzyme immunoassay for the in vitro qualitative or semiquantitative assay of amphetamines in human urine on automated clinical chemistry analyzers. Measurements are used as an aid in the detection of amphetamines use or overdose. For use in clinical laboratories only. CEDIA Amphetamines/Ecstasy is uniquely designed to recognize samples that contain any of the Ecstasy Drugs, a group of ring substituted methylenedioxy analogues of amphetamine including 3,4- methylenedioxyamphetamine (MDA), 3,4- methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA). This assay is intended for use on automated clinical analyzers. The assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography / mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug of abuse test result, particularly when | The DRI Ecstasy Enzyme Immunoassay is a homogeneous enzyme immunoassay intended for the qualitative or semiquantitative determination of ecstasy drugs in human urine. The assay provides a simple and rapid analytical screening procedure for detecting ecstasy drugs at a Cutoff level of 500 ng/mL. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. | | Device Name | CEDIA DAU Amphetamines/Ecstasy Assay (K010496) | DRI Ecstasy Enzyme Immunoassay (new device) | | Indications for Use (cont.) | preliminary positive results are used. The CEDIA Amphetamines/ Ecstasy Assay provides a choice of two cutoff levels: 500 and 1000 ng/mL The assay is appropriate for testing under the Substance Abuse and Mental health Services Administration (SAMHSA, formerly NIDA) guidelines, which currently recommends a cutoff of 1000 ng/mL | | | Method Principle | The assay uses recombinant DNA technology to produce a unique homogeneous enzyme immunoassay system. It is based on the bacterial enzyme β-galactosidase, which has been genetically engineered into two inactive fragments. These fragments spontaneously reassociate to form a fully active enzyme that, in the assay format, cleaves a substrate, generating a color change that can be measured spectrophotometrically. | The assay uses specific antibodies, which can detect ecstasy drugs in urine with minimal cross-reactivity to various amphetamine compounds. The assay is based on competition between a drug labeled with glucose-6- phosphate dehydrogenase (G6PDH) enzyme, and free drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the specific antibody binds the drug labeled with G6PDH causing a decrease in enzyme activity. This phenomenon creates a direct relationship between drug concentration in urine and enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH. | | Components | - Enzyme Acceptor Reagent - Enzyme Acceptor Buffer - Enzyme Donor Reagent - Enzyme Donor Buffer | - Antibody/Substrate Reagent - Enzyme Conjugate Reagent | | Risk to patient | In vitro device, positive results must be confirmed by GC/MS, or other method. | In vitro device, positive results must be confirmed by GC/MS, or other method. | | Clinical Performance | Accuracy: %Agreement against a GC/MS reference method was 95% (159 true positives, 18 true negatives); | Accuracy: %Agreement against a GC/MS reference method was 100% (92 true positives, 18 true negatives); | | | Total Imprecision: Percent dose CVs across 6 levels of amphetamines concentrations were between 7.8% and 9.2%. | Total Imprecision: Percent dose CVs across 3 levels of ecstasy concentrations were <2.5%. | DRI Ecstasy Enzyme Immunoassay vs CEDIA DAU Amphetamines/Ecstasy Assay {2}------------------------------------------------ · {3}------------------------------------------------ ## Brief Discussion of Nonclinical/Clinical Data (21 CFR 807.92(b)(1, 2)) The DRI Ecstasy Enzyme Immunoassay was evaluated via a series of traditional laboratory studies. These studies included the performance characteristics of sensitivity, linearity, specificity, precision, and accuracy. The assay showed good sensitivity with an LOD of 22 ng/mL. Precision studies indicated good reproducibility of results at the critical points of the measurement range (distinguishing positive from negative interpretations), as dose %CVs for both total and within-run testing were below 2.5%. The DRI Ecstasy Enzyme Immunoassay is linear between 375 and 625 ng/mL The assay also shows good separation in the decision-making ranges between 375 and 625 ng/mL. Accuracy studies showed good performance of the DRI Ecstasy Enzyme Immunoassay as compared to the GC/MS reference method. The %Agreement (Total) is 100%. Specificity testing demonstrated that the DRI Ecstasy Enzyme Immunoassay is not affected by common endogenous substances, variations in urinary pH levels, structurally unrelated pharmaceutical compounds, or potentially cross-reacting compounds. ### Performance Data - Conclusions (21 CFR 807.92 (b)(3)) The DRI Ecstasy Enzyme Immunoassay has been shown to be substantially equivalent to the predicate device, and safe and effective for its intended use. #### Conclusions The DRI Ecstasy Enzyme Immunoasay was evaluated via a series of traditional laboratory studies. These studies included the performance characteristics of sensitivity, linearity, specificity, precision, and accuracy. The assay showed good sensitivity with an LOD of 22 ng/mL. Precision studies indicated good reproducibility of results at the critical points of the measurement range (distinguishing positive from negative interpretations), as dose %CVs for both total and within-run testing were below 2.5%. The DRI Ecstasy Enzyme Immunoassay is linear between 375 and 625 ng/mL. The assay shows good separation in the decision-making ranges between 375 and 625 ng/mL. Accuracy studies showed excellent performance of the DRI Ecstasy Enzyme Immunoassay as compared to the GC/MS reference method. The %Agreement (Total) is 100%. Specificity testing demonstrated that the DRI Ecstasy Enzyme Immunoassay is not affected by common endogenous substances, variations in urinary pH levels, structurally unrelated pharmaceutical compounds, or potentially cross-reacting compounds. {4}------------------------------------------------ Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles a caduceus, with three wavy lines representing snakes intertwined around a staff. AUG 2 7 2001 Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Ms. Sherrie Gene Rinne Regulatory Specialist Microgenics Corporation 46360 Fremont Boulevard Fremont, CA 95438 Re: K012110 > Trade/Device Name: DRI® Ecstasy Enzyme Immunoassy Regulation Number: 21 CFR 862.3100 Regulatory Class: II Product Code: DKZ Dated: July 3 2001 Received: July 6, 2001 Dear Ms. Rinne: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition. FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {5}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed nouticate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, (201) 59 m 1500 - 1000 - 1000 - 1000 - 1000 - 4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small mornation on Jun 1000 consumer Assistance at its toll-free number (800) 638-2041 or 1401) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Sutman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ ## STATEMENT OF INTENDED USE 510(K) Number (if known): _KO12110 Device Name: DRI® Ecstasy Enzyme Immunoassay #### Indications for Use: The DRI Ecstasy Enzyme Immunoassay is a homogeneous enzyme immunoassay intended for the qualitative or semiquantitative determination of ecstasy drugs in human urine. The assay provides a simple and rapid analytical screening procedure for detecting ecstasy drugs at a Cutoff level of 500 ng/mL. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgement should be applied to any drug of abuse test result, particularly when preliminary positive results are used. ### (PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE AS NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use >> (Per 21 CFR 801.109) OR Over-the-Counter Use Kesia Alexander for Jean Cooper (Division Sign-Off) Laboratory Devices 510(k) Number Microgenics Corporation DRI Ecstasy Enzyme Immunoassay Page 13 of 32